氯沙坦、拜新同单独和联合治疗高血压患者疗效及患者靶器官损伤分析

Efficacy and target organ damage of losartan and adalat alone or combination therapy for hypertension

目的:探讨氯沙坦、拜新同单独和联合治疗高血压疗效及安全性。方法:收治高血压患者90例,随机分为3组,A组采用氯沙坦联合拜新同治疗,B组采用拜新同治疗,C组采用氯沙坦治疗,比较3组治疗效果和安全性。结果:3组总有效率差异无统计学意义(P>0.05);治疗后,3组的SiDBP、SiSBP明显低于治疗前(P<0.05),组间差异无统计学意义(P>0.05);治疗后,3组24 h尿白蛋白、24 h尿蛋白及血尿β2-MG明显低于治疗前(P<0.05),且A组的降低幅度明显大于B组和C组(P<0.05),而B组和C组差异无统计学意义(P>0.05)。治疗后,A组与C组的血尿酸明显低于治疗前(P<0.05)。治疗后,3组的血Cr和血BUN比较,差异无统计学意义(P>0.05)。结论:氯沙坦联合拜新同与氯沙坦、拜新同单独治疗高血压疗效差异无统计学意义,都能够降低患者靶器官损伤,但氯沙坦与拜新同联用对降低靶器官损伤有协同作用。

Objective:To explore the efficacy and security of losartan and adalat alone or combination therapy for hypertension.Methods:90 patients with hypertension were selected.They were randomly divided into 3 groups.A group was treated with losartan combined with adalat.B group was treated by adalat.C group was treated with losartan.We compared the treatment effect and safety of 3 groups.Results:There was no significant difference in the total effective rate among 3 groups(P>0.05).After treatment,SiDBP and SiSBP of 3 groups were significantly lower than before treatment(P<0.05),and there was no significant difference among 3 groups(P>0.05).After treatment,24 hours urinary albumin,24 hours urinary protein and hematuria β2-MG of 3 groups were significantly lower than before treatment(P<0.05),and the reduction degree of A group was significantly higher than that B group and C group(P<0.05),while there was no significant difference between B group and C group(P>0.05).After treatment,the serum uric acid levels of A group and C group were significantly lower than that before treatment(P<0.05).After treatment,there was no significant difference of blood Cr and BUN among 3 groups(P>0.05).Conclusion:There was no significant difference in therapeutic effect of losartan and adalat alone or combination therapy for hypertension.They can reduce target organ damage in patients,but losartan combined with adalat had synergistic effect for reducing the damage of target organs.